Objective: SBP variability may be a target for mitigating end-organ damage associated with vascular disease. We evaluated the relationship between increased SBP variability and risk of incident diabetic foot ulceration.
INTRODUCTION

E
xcessive SBP variability may offer a potential new target for mitigating end-organ damage associated with microvascular and macrovascular disease, such as diabetic foot ulcers [1] [2] [3] [4] [5] [6] . Foot ulcers typically arise whenever a minor injury goes unnoticed because of peripheral neuropathy (a microvascular complication) and fails to heal because of limb ischemia (a macrovascular complication) [7, 8] . Diabetic foot ulcers are one of the most common, yet neglected, manifestations of vascular disease [9] . Each year in the United States, an estimated 1.2 million patients develop a diabetic foot ulcer [10, 11] . In 2010, inpatient costs for diabetic foot ulcer treatment exceeded $790 million, and are trending upwards [12] . Emergency room care is also on the rise, with a 28% increase in the number of visits for treatment of diabetic foot ulcers [13] . Healthcare providers need novel targets to reduce the risk of foot ulceration and curb the burden of this common complication.
Over half of the 24 million Americans with diabetes are also hypertensive [10, 14] . Blood pressure (BP) control has both microvascular and macrovascular benefits in patients with diabetes [15] . However, focusing solely on reducing the absolute SBP ( 130 mmHg) may have diminishing returns for patients with diabetes [16] . Targeting SBP variability in addition to the absolute value, may help reduce the high risk of vascular complications faced by patients with diabetes. Increased SBP variability has previously been linked to myocardial infarction, stroke, peripheral neuropathy, retinopathy, and limb amputation [1] [2] [3] [4] [5] [6] . The goal of this study is to determine whether the risk of incident diabetic foot ulceration increases as SBP variability increases. SBP variability is modifiable and may provide a new therapeutic target for reducing diabetic foot ulcers at a time when their incidence is rising relatively unchecked [12, 13] .
METHODS
Study design and data sources
We used a nested case-control design to account for the time-dependent nature of SBP variability and to minimize selection bias [17, 18] . We selected cases and controls from a retrospective cohort of patients with diabetes. We defined cases as those patients who developed incident diabetic foot ulcers. Controls were required to be ulcer-free at least until the date when their corresponding case was diagnosed with a diabetic foot ulcer (index date). Controls could subsequently develop a foot ulcer and be included at that time as a case. Data [19] . We imposed a 2-year run-in period to exclude patients diagnosed with a diabetic foot ulcer or who died before 2006. The cohort was followed from 1 October 2005 (baseline) until 30 September 2010.
Cases
We defined cases as those individuals in the cohort who were diagnosed with an incident diabetic foot ulcer during the 5-year follow-up period [20, 21] . The cohort run-in period allowed us to identify incident, rather than prevalent, foot ulcers. Foot ulceration was identified using validated ICD-9-CM codes present in in-patient and out-patient datasets (n ¼ 85 086) [21] . For patients with multiple foot ulcerations, either because of recurrence or development on the contralateral foot, we used the first diagnosis only.
Controls
Controls were selected from all individuals in the cohort who did not develop an incident foot ulcer by the corresponding case's index date. Controls were matched for age, sex, race/ethnicity, and calendar time. Up to five controls were randomly selected for each case (n ¼ 340 344; average four controls per case) [17, 18] .
SBP variability
All out-patient BP measurements obtained in the VA system (excluding the emergency room) in the 365 days preceding the index date were considered. We excluded measures taken between 2200 and 0800 h because they were most likely measured during hospital stays or emergency room visits. Those with SBP readings between 50 and 300 mmHg and those with DBP readings between 30 and 180 mmHg were accepted. Multiple BP readings taken on the same day were averaged and counted as one reading. For patients with more than 12 BP measurements during the 365 days preceding the index date, we randomly selected 12 to use when calculating the mean SBP and SBP variability, in accordance with Rothwell et al.'s [3] established method for calculating SBP variability. Cases and controls with less than three accepted BP measurements in the preceding year were excluded (leaving n ¼ 52 748 cases, 202 302 controls). After these exclusions, we dropped 1637 cases because of lack of controls and 73 055 controls missing a case. The final sample included 180 358 individuals, of whom 51 111 were cases and 129 247 were controls (Fig. 1) .
We computed the within-subject mean and SD of SBP and DBPs based on all accepted BP measurements. We calculated the SBP variability independent of the mean because mean and SD in BP tend to be correlated, such that persons with higher BP readings tend to have more variability [3, 22] . Calculating SBP variability in this manner allows any subsequent associations to be attributed to the SBP variability rather than the SBP mean.
Covariates
We identified covariates known to be associated with the risk of diabetic foot ulcers to reduce confounding [23] [24] [25] [26] . Demographic variables were assessed at baseline only. All other variables were time-dependent and assessed in the 365-day period preceding the index date. When more than one measurement or result was available, we used the average value. When no measurement or result was available, we categorized the value as 'unknown' and kept the patients in the analysis. When assessing medications, we defined patients as users of a medication if they had received at least a 30-day supply in the preceding year. For antihypertensive medications, we separately identified the use of calcium channel blockers, beta blockers, and all other antihypertensive medications. These groups are not mutually exclusive because patients could be on combination therapies.
Demographic factors
As we matched cases and controls on age, sex, and race/ ethnicity, these were not included in the regression models. The only demographic variable we included in the model was baseline marital status.
Diabetes-related variables
We estimated diabetes severity using the following metrics: duration of diabetes, hemoglobin A1C level, hypoglycemic medications, and diabetes complications such as neuropathy. We determined diabetes duration by identifying the first time, between 1997 and the baseline, for which an ICD-9-CM code for diabetes was recorded. We used the year 1997 because this is when VA electronic medical records data are available for research. We assessed the following diabetes complications as a measure of diabetes severity and risk factors for foot ulceration: renal failure, retinopathy, neuropathy, Charcot arthropathy, and the presence of a foot deformity [23, 25, 26] . We included the number of podiatry clinic visits in the preceding year to help account for characteristics that may have placed the patient at high risk of ulceration but may not have been captured in claims coding.
Variables related to vascular disease
We included the following parameters associated with vascular disease because this is also a major risk factor for ulceration: chronic venous stasis, peripheral vascular disease, low-density lipoprotein (LDL) cholesterol values, and use of cholesterol-lowering agents [23, 24] .
Other systemic factors
We included BMI, calculated using measured heights and weights, and serum albumin levels as a marker of overall nutritional status [27] . To further ensure that any measured differences were attributed to SBP variability, rather than the SBP mean, we controlled for the mean SBP in all adjusted models.
Statistical analysis
We examined the association between SBP variability and development of a diabetic foot ulcer using conditional logistic regression to account for the matched case-control design. To model SBP variability, cases and controls were divided into quartiles with quartile 1 as the lowest variability group. We obtained odds ratios (ORs) and 95% confidence intervals (CIs) from unadjusted and adjusted models that included all covariates described above.
We conducted sensitivity analyses to test whether any relationship between SBP variability and foot ulceration was influenced by the presence of hypertension, or the number of BP readings used to calculate variability. Hypertension was defined as a mean, absolute blood pressure greater than or equal to 130/80 mmHg or use of antihypertensive agents. Participants were categorized as having six or fewer (versus seven or more) BP readings used to calculate their SBP variability. Interaction terms between SBP variability and hypertenstion, or the number of BP readings were entered into the main, adjusted model.
We also conducted a secondary analysis to explore the possible protective effects of calcium channel blockers, which have been associated with reduced blood pressure variability and may moderate the effect of SBP variability on foot ulceration [22, 28] . If vascular and neurologic damage mediates the association between SBP variability and diabetic foot complications, as we previously hypothesized, then taking calcium channel blockers may be protective for patients who have not yet developed vascular or neurologic deficits [4] . However, this drug class would be less likely to reduce the risk of foot ulcers for patients with existing peripheral vascular disease or neuropathy. To test our hypothesis, we constructed three models. First, we added use of antihypertensives (calcium channel blockers, beta blockers, or other antihypertensives) to the main model. We expected that calcium channel blocker use would protect against foot ulcers, but not use of beta blockers or other antihypertensive medications. Second, we added an interaction term between peripheral vascular disease and our three antihypertensive drug class variables. Third, we added an interaction term between neuropathy and our antihypertensive drug classes. We expected that the interaction terms would not meet statistical significance, indicating that any protective association of the 
Ã As the same individual could be selected into multiple risk sets as both cases and controls, we reported the unique number of excluded patients from the inception cohort. For this reason, the numbers in the two boxes with asterisks do not add up to the total number in the inception cohort.
antihypertensive seen in the first model would be limited largely to patients without peripheral vascular disease (model 2) or neuropathy (model 3). All analysis was conducted using SAS 9.4 (SAS Institute, Cary, North Carolina, USA) and Stata SE 14 (StataCorp, College Station, Texas, USA).
RESULTS
Over half the sample was at least 55 years old; 98.3% were men, and 73.7% were non-Hispanic whites. Cases (n ¼ 51 111) and controls (n ¼ 129 247) were well matched in terms of age, sex, and race/ethnicity (Supplemental Digital Content 2, http://links.lww.com/HJH/A942). Cases tended to have more BP measures than controls (7.8 vs 7.0, P < 0.001). Cases tended to have more poorly controlled diabetes despite more aggressive hypoglycemic regimens than controls. Compared with controls, they were also more likely to be diagnosed with peripheral vascular disease despite lower LDL cholesterol values. Cases also were more likely to have hypoalbuminemia and chronic venous stasis (Table 1) . These comorbidities were associated with increased odds of foot ulceration. Cases also had a shorter duration of diabetes than controls, which was associated with increased odds of foot ulceration in this study. All of these variables remained significant in the adjusted models.
Mean SBP was slightly lower for cases than controls (135.0 AE 15.0 versus 135.5 AE 13.8 mmHg, P < 0.001). Mean 12 ) and, compared with those in quartile 3, patients in quartile 4 had 7% higher risk (OR ¼ 1.07; 95% CI 1.03-1.11) of foot ulceration. There was also a significant graded relationship between SBP variability and foot ulceration risk (P value for trend <0.001; Table 1 ). Our sensitivity analysis confirmed that the relationship between SBP variability and foot ulceration held in those with and without hypertension, as well as those whose SBP variability was calculated using less than six or seven or more BP measurements (P for trend <0.001 for both groups; Table 2 ).
Increased SBP variability remained associated with an increased risk of incident foot ulcers in the antihypertensive secondary analysis (Table 3) . Calcium channel blockers were protective against developing a foot ulcer, a finding that was specific to this antihypertensive drug class (OR ¼ 0.88; 95% CI 0.86-0.91; P < 0.001, Model 1, Table  3 ). They remained protective for those without peripheral vascular disease (OR ¼ 0.89; 95% CI 0.86-0.92; P < 0.001, Model 2) and for those without peripheral neuropathy (OR ¼ 0.88; 95% CI 0.84-0.91; P < 0.001, Model 3), but not with either comorbidity (P for interaction ¼ 0.150 for peripheral vascular disease; 0.303 for neuropathy). Table C shows that SBP mean and variability were greater among users compared with nonusers for all three classes of antihypertensive medications (P < 0.001 for all comparisons, Supplemental Digital Content 4, http://links. lww.com/HJH/A942). 
DISCUSSION
This is the first study to demonstrate a graded relationship between excessive SBP variability and increased risk of developing a diabetic foot ulcer, independent of the mean SBP. After controlling for most major risk factors for foot ulceration such as peripheral vascular disease, peripheral neuropathy, and foot deformity, the risk of ulceration increased linearly in each successive quartile and the largest variability group (quartile 4) had almost 30% higher risk of foot ulceration than the least variability group (quartile 1). We also found similar graded relationships for both normotensive and hypertensive patients as determined by both BP 130/80 mmHg thresholds and antihypertensive use. This graded relationship, which held for individuals with and without hypertension, suggests that SBP variability is not just an epiphenomenon of elevated absolute SBP but a potential, independent, and modifiable risk factor warranting further study. Excessive SBP variability has been previously linked to increased risk of macrovascular complications such as myocardial infarction, stroke, and above-ankle (major) amputation [1] [2] [3] [4] . SBP variability has also been associated with increased risk of microvascular complications, such as nephropathy and retinopathy [5, 6] . Underlying macrovascular and microvascular diseases are dominant risk factors for development of a diabetic foot ulcer; therefore, our finding that excessive SBP variability is associated with an increased risk in foot ulceration is consistent with prior knowledge. SBP variability offers a potential new and modifiable target for clinicians to reduce the burden of diabetic foot ulcers. Comparisons between SBP variability quartiles suggest that the relationship between SBP variability and incident foot ulceration is linear and may have a potential inflection point around the within-patient SD of 5 mmHg (the cut-off between quartiles 1 and 2), corresponding to an increased risk of $11%. This threshold is consistent with previous studies [3, 29] .
Our analysis confirms the importance of classic risk factors for incident foot ulceration. Elevated hemoglobin A1C levels, vascular disease, foot deformities, and microvascular complications such as renal failure, neuropathy, and retinopathy, remained predictive of developing an incident ulcer in our model. In our study, a longer duration of diabetes was associated with a reduced risk of incident foot ulceration. Although the exact reason for this finding is unknown, we suggest three possibilities. First, it may be a result of studying incident, rather than prevalent, foot ulcers. Prevalence increases with duration of diabetes, but incident ulcers may peak in those with shorter durations [30] . Second, it is possible that patients with newly diagnosed diabetes had suboptimal diagnosis and control of comorbid risk factors, placing them at increased risk of foot ulceration. As the length of diagnosed diabetes increased, it may have provided time to diagnosis and manage those comorbidities, thereby reducing the risk of foot ulceration. Third, many of the risk factors that predispose to ulceration also increase the risk of death, introducing the possibility of survival bias [31] .
In our secondary analysis, we found that calcium channel blockers were associated with a reduced risk of incident diabetic foot ulcers. Previous studies suggested that calcium channel blockers (especially the dihydropyridine subclass) blunt within-patient SBP variability [32] . Comparisons between calcium channel blocker users and nonusers in our data found a higher SBP variability in those taking calcium channel blockers. As our data set is cross-sectional, not longitudinal, it does not contain information on individual patients before and after drug administration that would be needed to comment on whether calcium channel blockers decrease SBP variability within individuals. Our results do suggest that potential benefits of calcium channel blockers were limited to patients without previously diagnosed peripheral vascular disease or neuropathy. Once vascular and neurologic damage has occurred, it may be too late for calcium channel blockers to decrease the risk of ulceration. In our prior study demonstrating that increased SBP variability was associated with an increased risk of major amputation, calcium channel blockers were not protective in a model that included more proximal determinants of major amputation, such as foot ulcers, neuropathy, and vascular disease [4] . Taken together, our current and prior studies suggest that if calcium channel blockers mitigate the risk of diabetic foot ulcers, their impact is likely to be maximized when they are initiated soon after diabetes is diagnosed and before vascular comorbidities, such as peripheral vascular disease and neuropathy, can develop. Early use of calcium channel blocker is aligned with current antihypertensive guidelines, which state that, for patients without albuminuria for whom vascular disease prevention is the primary goal, dihydropyridine calcium channel blockers may be considered instead of, or in addition to, an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) [33] .
Although our nested case-control study cannot establish a causal relationship between SBP variability and incident diabetic foot ulcers, it contributes to building a case for it. In Table 4 , we review epidemiologic guidelines used to determine whether an association is causal, highlighting areas of established strength and current weaknesses ripe for further investigation [34] . Key contributions from this study include: establishing an association between SBP variability and incident diabetic foot ulcers comparable with known risk factors such as neuropathy, quantifying a doseresponse relationship between SBP variability and foot ulceration, and documenting that calcium channel blockers, which reduce exposure to SBP variability, are associated with a reduced risk of ulceration [32] . Establishing a causal relationship would require prospectively replicating the findings in different populations using stronger study designs. Potential future studies include prospective cohorts and randomized clinical trials of interventions that might blunt SBP variability among patients with newly diagnosed diabetes to prevent foot ulceration. Additional pathophysiologic work would also bolster the argument for a causal relationship between SBP variability and diabetic foot ulcers.
The current study's design strengths include that the cohort was compiled from the VA national databases and represented a geographically diverse population with SBP measurements extracted from real-life clinical data. We carefully selected these measures to reflect the SBP variability individuals experience during routine, outpatient care, excluding any readings taken from hospitalizations, emergency room visits or in the night time. We used sensitivity analyses to exclude potential confounding by the number of BP measures as an alternative explanation for the relationship between SBP variability and foot ulceration risk.
We also recognize several limitations to be considered when interpreting our results. First, this is a retrospective observational study, which raises concern for bias because of confounding. We did not have access to some potential confounding factors that may have affected both SBP variability and the risk of amputation, such as smoking or medication adherence, in our dataset. Medication adherence, for example, can affect both SBP variability and the risk of foot ulceration. Although we controlled for other risk factors, such as the extent of diabetes control and hypoglycemic regimens, cases had many more risk factors for ulceration than controls, raising the possibility of residual confounding. Second, retrospective observational studies are also prone to selection bias. The nested case-control design by which controls were randomly selected from a large cohort of individuals at risk of developing a foot ulcer during the timespan in which a case occurred, helps to mitigate this bias [18] . Third, we relied on administrative claims data to identify comorbidities and the clinical outcome, raising the possibility of misclassification. Even though foot ulcers can be determined with very high accuracy using VA administrative data, we acknowledge that nonsymptomatic peripheral vascular disease may have been under-identified in our data set [21] . Lastly, as is typical with VA studies, the cohort from which cases and controls were selected was largely men, which raises the question as to whether results are generalizable to women with diabetes.
In conclusion, excessive SBP variability is associated with an increased risk of developing a diabetic foot ulcer. This study lays a foundation for further investigations into a causal relationship. Firmly establishing increased SBP variability as a causative factor leading to diabetic foot ulcers would allow providers to target this modifiable risk. Reducing SBP variability soon after the initial diagnosis of diabetes may prove useful in preventing one of the most common, debilitating, and costly complications of diabetes [7, 9, 12] . In addition to diabetic foot ulcers, increasing SBP variability has been associated with other microvascular and macrovascular complications [1] [2] [3] [4] [5] [6] Data from [34] .
